Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE versus STATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE versus STATROL.
HYDROCORTISONE vs STATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. This results in anti-inflammatory, immunosuppressive, anti-proliferative, and vasoconstrictive effects. It also modulates carbohydrate, protein, and lipid metabolism.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Oral: 10-20 mg every 6-8 hours; IV/IM: 100-500 mg every 2-6 hours for acute conditions; typical maintenance: 20-240 mg/day divided every 8-12 hours.
10 mg orally once daily
None Documented
None Documented
Clinical Note
moderateHydrocortisone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin."
Clinical Note
moderateHydrocortisone + Rosoxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin."
Clinical Note
moderateHydrocortisone + Levofloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 1.5–2 hours (plasma). In tissues, biologic half-life is 8–12 hours due to intracellular activity. Half-life prolonged in hepatic impairment.
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: primarily as inactive metabolites (cortisone, tetrahydrocortisone) and unchanged drug (<1%). Biliary/fecal: minimal (<5%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Category D/X
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid
Hydrocortisone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin."